These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 12604557)

  • 1. Postantibiotic effects of garenoxacin (BMS-284756) against 12 gram-positive or -negative organisms.
    Pankuch GA; Jacobs MR; Appelbaum PC
    Antimicrob Agents Chemother; 2003 Mar; 47(3):1140-2. PubMed ID: 12604557
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Postantibiotic effect of trovafloxacin against gram-positive and -negative organisms.
    Pankuch GA; Jacobs MR; Appelbaum PC
    Antimicrob Agents Chemother; 1998 Jun; 42(6):1503-5. PubMed ID: 9624503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Postantibiotic effects of gatifloxacin against gram-positive and -negative organisms.
    Pankuch GA; Jacobs MR; Appelbaum PC
    Antimicrob Agents Chemother; 1999 Oct; 43(10):2574-5. PubMed ID: 10508050
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Postantibiotic effect of DX-619 against 16 gram-positive organisms.
    Pankuch GA; Appelbaum PC
    Antimicrob Agents Chemother; 2005 Sep; 49(9):3963-5. PubMed ID: 16127083
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Commercial broth microdilution panel validation and reproducibility trials for garenoxacin (BMS-284756), a novel desfluoroquinolone.
    Gordon KA; Rhomberg PR; Jones RN
    J Clin Microbiol; 2003 Aug; 41(8):3967-9. PubMed ID: 12904431
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Postantibiotic effect of tigecycline against 14 gram-positive organisms.
    Pankuch GA; Appelbaum PC
    Antimicrob Agents Chemother; 2009 Feb; 53(2):782-4. PubMed ID: 19064899
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Postantibiotic effect of ceftobiprole against 12 Gram-positive organisms.
    Pankuch GA; Appelbaum PC
    Antimicrob Agents Chemother; 2006 Nov; 50(11):3956-8. PubMed ID: 17065631
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Postantibiotic effects of telavancin against 16 gram-positive organisms.
    Pankuch GA; Appelbaum PC
    Antimicrob Agents Chemother; 2009 Mar; 53(3):1275-7. PubMed ID: 19124659
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Postantibiotic sub-MIC effects of vancomycin, roxithromycin, sparfloxacin, and amikacin.
    Odenholt-Tornqvist I; Löwdin E; Cars O
    Antimicrob Agents Chemother; 1992 Sep; 36(9):1852-8. PubMed ID: 1329631
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Postantibiotic effect and postantibiotic sub-MIC effect of quinupristin-dalfopristin against gram-positive and -negative organisms.
    Pankuch GA; Jacobs MR; Appelbaum PC
    Antimicrob Agents Chemother; 1998 Nov; 42(11):3028-31. PubMed ID: 9797249
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Postantibiotic effects of grepafloxacin compared to those of five other agents against 12 gram-positive and -negative bacteria.
    Spangler SK; Bajaksouzian S; Jacobs MR; Appelbaum PC
    Antimicrob Agents Chemother; 2000 Jan; 44(1):186-9. PubMed ID: 10602746
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Postantibiotic effects of E-4868 and OPC-17116.
    Sanford MD; Jones RN
    J Antimicrob Chemother; 1993 Dec; 32(6):916-7. PubMed ID: 8144440
    [No Abstract]   [Full Text] [Related]  

  • 13. Pharmacodynamic studies of trovafloxacin and grepafloxacin in vitro against Gram-positive and Gram-negative bacteria.
    Odenholt I; Cars T; Lowdin E
    J Antimicrob Chemother; 2000 Jul; 46(1):35-43. PubMed ID: 10882686
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacodynamic properties of BAY 12-8039 on gram-positive and gram-negative organisms as demonstrated by studies of time-kill kinetics and postantibiotic effect.
    Boswell FJ; Andrews JM; Wise R
    Antimicrob Agents Chemother; 1997 Jun; 41(6):1377-9. PubMed ID: 9174203
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antimicrobial activity of a novel des-fluoro (6) quinolone, garenoxacin (BMS-284756), compared to other quinolones, against clinical isolates from cancer patients.
    Rolston KV; Frisbee-Hume S; LeBlanc BM; Streeter H; Ho DH
    Diagn Microbiol Infect Dis; 2002 Oct; 44(2):187-94. PubMed ID: 12458127
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activities of garenoxacin (BMS-284756) and other agents against anaerobic clinical isolates.
    Hecht DW; Osmolski JR
    Antimicrob Agents Chemother; 2003 Mar; 47(3):910-6. PubMed ID: 12604521
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro assessment of the postantibiotic effect of lomefloxacin against gram-positive and gram-negative pathogens.
    Debbia EA; Pesce A; Schito GC
    Am J Med; 1992 Apr; 92(4A):45S-47S. PubMed ID: 1316070
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative activity of the new fluoroquinolone rufloxacin (MF 934) against clinical isolates of gram-negative and gram-positive bacteria.
    Qadri SM; Ueno Y; Postle G; Tullo D; San Pedro J
    Eur J Clin Microbiol Infect Dis; 1993 May; 12(5):372-7. PubMed ID: 8394816
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potency and spectrum of garenoxacin tested against an international collection of skin and soft tissue infection pathogens: report from the SENTRY antimicrobial surveillance program (1999-2004).
    Fritsche TR; Sader HS; Jones RN
    Diagn Microbiol Infect Dis; 2007 May; 58(1):19-26. PubMed ID: 17383139
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activities of clinafloxacin, alone and in combination with other compounds, against 45 gram-positive and -negative organisms for which clinafloxacin MICs are high.
    Clark CL; Jacobs MR; Appelbaum PC
    Antimicrob Agents Chemother; 1999 Sep; 43(9):2295-8. PubMed ID: 10471582
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.